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The functions of bone marrow plasma cells (BMPC) beyond antibody production are not
fully elucidated and distinct subsets of BMPC suggest potential different functions.
Phenotypic differences were identified for human BMPC depending on CD19
expression. Since CD19 is a co-stimulatory molecule of the B-cell-receptor (BCR), and
IgA+ and IgM+ BMPC express the BCR on their surface, we here studied whether CD19
expression affects cellular responses, such as BCR signaling and the expression of
checkpoint molecules. We analyzed 132 BM samples from individuals undergoing routine
total hip arthroplasty. We found that both CD19+ and CD19− BMPC expressed BCR
signaling molecules. Notably, the BCR-associated kinase spleen tyrosine kinase (SYK)
including pSYK was higher expressed in CD19+ BMPC compared to CD19− BMPC. BCR
stimulation also resulted in increased kinase phosphorylation downstream of the BCR
while expression of CD19 remained stable afterwards. Interestingly, the BCR response
was restricted to IgA+ BMPC independently of CD19 expression. With regard to the
expression of checkpoint molecules, CD19− BMPC expressed higher levels of co-
inhibitory molecule programmed cell death protein-1 (PD-1) than CD19+ BMPC. IgA+
BMPC characteristically upregulated PD-1 upon BCR stimulation in contrast to other PC
subsets and inhibition of the kinase SYK abrogated PD-1 upregulation. In contrast,
expression of PD-1 ligand, B and T lymphocyte attenuator (BTLA) and CD28 did not
change upon BCR activation of IgA+ BMPC. Here, we identify a distinct characteristic of
IgA+ BMPC that is independent of the phenotypic heterogeneity of the subsets according
to their CD19 expression. The data suggest that IgA+ BMPC underlie different regulatory
principles and/or exert distinct regulatory functions.
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Human serum antibody titers are relatively stable and exhibit
half-lives ranging from years to decades (1). They are produced
by plasma cells (PC) located in the bone marrow (BM), which
have a unique transcriptome with >70% of transcripts encoding
the immunoglobulin heavy (IgH) and light (IgL) chains (2). Of
these BMPC, a subset is considered to be long-lived producing
IgG with half-live times above 10.000 years (1, 3).
We and others described a subset of BMPC lacking the
costimulatory molecule CD19 (4–7). CD19 enhances signaling
downstream of the B cell receptor (BCR) by lowering the
threshold for its activation (8). Consistently, genetic loss of
CD19 results in immune deficiency (9), while elevated CD19
expression has been detected in autoimmune diseases (10, 11).
CD19− BMPC display markers of advanced maturity and seem to
contain a higher amount of long-lived PC than their CD19-
expressing counterparts (4, 5), they persist after CD19-directed
chimeric antigen receptor (CAR) T-cell therapy in B cell
malignancies and produce IgG specific to tetanus toxoid,
mumps and measles (12). In peripheral blood, low frequencies
of CD19low/CD19− plasmablasts have been identified during the
acute response to influenza vaccination and steady state (6).
In contrast to previous assumptions that BMPC lack surface
Ig (13), it was reported that IgA and IgM are present on the
surface and functionally active (7, 14, 15). IgA+ and IgM+ BMPC
have been shown to respond to BCR stimulation with spleen
tyrosine kinase (SYK) and extracellular-signal regulated kinase
(ERK) phosphorylation (14).
In this study, we show that BCR signaling is distinct among
CD19+ versus CD19− BMPC. Components of the BCR signaling
pathway are expressed in both subsets, but the signaling kinase SYK
and pSYK Y352 are higher expressed in CD19+ BMPC. Non-IgG
BMPC react to BCR stimulation enhancing phosphorylation of
BCR-associated kinases and characteristically upregulate the co-
inhibitory molecule programmed cell death protein 1 (PD-1) in
response to BCR ligation independently of their CD19 expression
which can be abrogated using a SYK inhibitor. This indicates that
IgA+ PC fulfill distinct immune functions likely related to antigen
encounter and that their regulation involve PD-1 expression.MATERIALS AND METHODS
Donors
132 BM samples were obtained from patients (71 women, 61
men; 67 ± 10 years (mean ± SD); range, 41–92 years) undergoing
total hip arthroplasty. The study was approved by the local ethics
committee of Charité Universitätsmedizin Berlin in accordance
with the declaration of Helsinki and written informed consent
was obtained from all patients.
Isolation of Mononuclear Cells
Mononuclear cells (MNCs) from the BM were isolated as
described previously (4). Briefly, samples were fragmented,
rinsed with PBS (Biochrom, Berlin, Germany) for cell cultureFrontiers in Immunology | www.frontiersin.org 2and stimulation or with PBS/0.5%BSA/EDTA (PBE) (Miltenyi
Biotech, Bergisch Gladbach, Germany) for staining, and filtered
with a 70 μm cell strainer (BD Biosciences, Heidelberg,
Germany). The obtained cell suspension was subjected to a
density gradient centrifugation with Ficoll Paque (GE
Healthcare, Buckinghamshire, UK) and/or used for whole BM
stainings. The collected mononuclear cells were washed twice
with PBS or PBE and either resuspended in RPMI 1640
(ThermoFisher Scientific, Waltham, MA, USA) for stimulation
assays or in PBE for staining.
Enrichment of Bone Marrow Plasma Cells
by Magnetic-Activated Cell Sorting
MNCs from the BMwere incubated with CD3-, CD14- andCD235a-
microbeads and subjected to magnetic-activated cell sorting (MACS)
according to the manufacturer’s protocol. Afterwards, cells were
stained and sorted with a FACS Aria II (BD Biosciences). For some
cell culture experiments, BMPC were enriched with CD138
microbeads according the manufacturer’s instructions.
Whole Bone Marrow Staining
Filtered cell suspension was lysed with prewarmed 1× Lyse/Fix
buffer (BD Biosciences). After centrifugation and washing with
ice-cold PBS, cells were permeabilized with Perm Buffer II (BD
Biosciences) according to the manufacturer’s protocol and as
described previously (16). Subsequently, the cells were washed
with PBE and stained intracellularly.
Stainings for Flow Cytometry
2 × 106 MNCs were surface-stained for 15 min at 4°C or for 1 h at
room temperature (RT) for intracellular staining with different
combinations of antibodies (Table S1). DAPI (Molecular Probes,
Eugene, USA) or LIVE/DEAD Fixable Blue Dead Cell Stain Kit
(ThermoFisher Scientific) were used to exclude dead cells
according to the manufacturer’s protocol. Cells were analyzed
with a FACS Canto II or LSR Fortessa X-20 flow cytometer in
standard configuration (BD Biosciences). PC, BC and T cells
were identified as previously described (17) (Figure S1) and
BMPC subsets were sorted. For quality control, Cytometer Setup
& Tracking Beads (BD Biosciences) and SHPERO Calibration
Particles (BD Biosciences) were used to get reproducible median
fluorescence intensities (MFI). Staining controls were either done
by fluorescence minus one (FMO) or isotype control approach.
For assessment of absolute counts, cells were resuspended in a
defined volume after staining and 20 μl of CountBright™
Absolute Counting Beads (ThermoFisher Scientific) were






  =   cells=μl
Microarray for Transcriptome Analysis
Analysis of transcriptomes of CD19+ and CD19− BMPC was
performed as previously described (4) (GEO accession
number GSE56464).February 2021 | Volume 11 | Article 628923
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RNA of CD19+IgA+, CD19+IgA−, CD19−IgA+, and CD19−IgA−
sorted cells was isolated by using the RNeasy Micro Kit (Qiagen,
Hilden, Germany) following the manufacturer’s instructions.
A modified SmartSeq 2 protocol was performed; total RNA
between 2 and 10 ng was used as input for the reverse
transcription. RNA was primed by adding 1 μM Oligo-dT
Primer (final conc. ; 5′AAGCAGTGGTATCAACGCA
GAGTACTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTVN;
V = A/C/G, N = any base), 1 mM dNTPs (final conc.) followed
by a denaturation at 72°C for 3 min and immediately cooling on
ice. Reverse transcription was performed in a 10-μl volume
reaction by using 0.5 μl Superscript II RT (200 U/μl, Thermo
Fisher Scientific), 0.4 μl RNAse inhibitor (40 U/μl, Promega,
Madison, USA), 5 mM DTT, 1 M Betaine, 6 mM MgCl2 and 1
μM TSO (B-AAGCAGTGGTATCAACGCAGAGTACAT997,
B = 5′ biotin, 7 = LNA g, 9 = RNA-G) under the following
incubation conditions: 42°C for 90 min, 10× cycling of 50°C for
2 min and 42°C for 2 min, finalized by 70°C for 15 min. The
preamplification of the cDNA was carried out by utilizing the
KAPA HiFi HotStar Ready Mix (Roche, Basel, Switzerland) and
0.1 μM of the IS PCR primers (5´AAGCAGTGGTATCAACGC
AGAGT) in a 25 μl volume reaction under the following PCR
conditions: 98°C for 3 min, 10× cycling of 98°C for 20 s, 67°C for
15 s, 72°C for 6 min and a final elongation at 72°C for 5 min. The
cDNA was purified by the use of 1× Agencourt AMPure XP
Beads (Beckman Coulter, Brea, CA, USA), quantified by the help
of Qubit® dsDNA HS Assay Kit (Thermo Fisher Scientific) and
the cDNA integrity was examined via the analysis of the
fragment size distribution by using the Agilent 2100
Bioanalyzer (High Sensitivity DNA Analysis Kit, Agilent, Santa
Clara, CA, USA).
The libraries were prepared by applying a tagmentation based
approach using the Nextera DNA Library Preparation Kit
(Illumina, San Diego, CA, USA). 8 ng of each cDNA were
tagmented for 10 min at 55°C by the use of 1 μl of the
Tagment DNA Enzyme 1 in a 20 μl reaction pursued
immediately by the purification of the tagmented fragments by
the use of the MinElute PCR Purification Kit (Qiagen) following
the manufacturer’s instructions. The amplification of the
libraries was performed in a 30 μl reaction using the NEBNext
High-Fidelity 2× PCR Master Mix (New England Biolabs,
Ipswich, MA, USA) and 0.33 μM indexed adapters (5′
AATGATACGGCGACCACCGAGATCTACAC[i5]TCGTC
GGCAGCGTC and 5′CAAGCAGAAGACGGCATACGAGAT
[i7]GTCTCGTGGGCTCGG; Illumina). 8 PCR cycles were done
of the following PCR program: 75°C 5 min, 98°C 10 s, cycling of
98°C 30 s, 63°C 30 s and 7°C 1 min, finalized by a long elongation
at 72°C for 7 min. The libraries were purified by utilizing 0.9×
Agencourt AMPure XP Beads (Beckman Coulter), the DNA
concentrations were quantified by the help of the Qubit® dsDNA
HS Assay Kit (Thermo Fisher Scientific) and the size distribution
of the amplified fragments was examined by the use of the
Agilent 2100 Bioanalyzer (High Sensitivity DNA Analysis Kit,
Agilent). The libraries were sequenced on the Illumina HiSeq
2500 by using the 100 bp single read sequencing mode.Frontiers in Immunology | www.frontiersin.org 3mRNA Seq Data Processing
Adapter-sequences of FastQ format RNA-seq reads were
removed and the reads were trimmed of low quality ends
(phred score = 20) by the use of Trim Galore! (version 0.4.2)
(“Babraham Bioinformatics - Trim Galore!” 2017). The reads
were aligned to the hg38 reference genome (Genbank:
GCA_000001405.15) by using grape-nf (version 433e7621f6)
(18), which combines STAR (version 2.4.0j) (19) for the
alignment and RSEM (version 1.2.21) (20) for the
read assignment.
B Cell Receptor Stimulation
For short-term kinetics, 2 × 106 MNCs were equilibrated with
RPMI 1640 at 37°C for 30 min and stimulated with 30 μg/ml
anti-IgM/IgG/IgA (Jackson ImmunoResearch, Ely, UK), 10 μg/
ml anti-IgA (Jackson ImmunoResearch) or 10 μg/ml anti-IgG
(Jackson ImmunoResearch) for the indicated times. To assess
baseline phosphorylation (0 min), cells were treated with RPMI
for 5 min. Reaction was stopped using 1× Lyse/Fix Buffer (BD
Biosciences) and cells were permeabilized with Perm Buffer II
(BD Biosciences) according to the manufacturer’s protocol,
washed with PBE and stained intracellularly. In some
experiments, cells were pre-incubated with SYK inhibitor
entospletinib (GS-9973, Selleck Chemicals, final concentration
10 μM), BTK inhibitor acalabrutinib (ACP-196, Selleck
Chemicals, final concentration 100 μM) or DMSO as control
for 1h prior to stimulation with anti-BCR.
For cell culture, 2 to 3 × 106 MNCs were seeded in a 96-Well
plate (BD Falcon) with medium as described in the final
incubation step for long-lived PC (21) including interleukin
(IL-) 6 and a proliferation-inducing ligand (APRIL). 1 μg/ml
anti-BCR F(ab)2 IgM/IgG/IgA (Jackson ImmunoResearch) or 0.5
μg/ml crosslinked CD40L (Miltenyi) were added to the culture
and cells were cultured at 37°C and 5% CO2 in a humidified
incubator for up to four days. In some experiments, cells were
pre-incubated with SYK inhibitor entospletinib (final
concentration 10 μM) or DMSO as control for 30 min prior to
stimulation with anti-BCR. Concentrations of stimulating agents
and inhibitors were titrated in previous experiments.
Data and Statistical Analysis
Flow cytometric data was analyzed with FlowJo version 7.6.5 or
10.1 (FlowJo LLC, BD Biosciences). Statistical analysis was
performed with GraphPad Prism 6 or 8 software (Graphpad
Software, San Diego, CA, USA). Statistical significance was tested
as indicated.RESULTS
CD19+ and CD19− Bone Marrow Plasma
Cells Express B Cell Receptor-Associated
Molecules
To assess whether CD19+ and CD19− BMPC both have the
prerequisites for BCR signaling, CD19+ and CD19− BMPC gene
expression was analyzed for BCR-associated molecules (GEOFebruary 2021 | Volume 11 | Article 628923
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as presence or absence of the CD19 transcript could be
confirmed and classical markers of other lineages were not
detected (Figure 1A). Regarding the capability of BCR
signaling, the analysis showed that transcripts of molecules
relevant for BCR signaling are found in both CD19+ and
CD19− BMPC, among them e.g. BCR components (CD79A,
CD79B), BCR co-stimulating receptors (CD21, CD81), protein
tyrosine kinases (PTKs) and protein serine/threonine kinases
(PSKs, SYK, PLCG2, BTK, AKT3) but also BCR associated
phosphatases (PTPN6, INPP5D). In this analysis, a similar
expression of the aforementioned molecules was found for
both CD19+ and CD19− PC on the mRNA level.
Next, we measured protein expression of representative
downstream PTKs (SYK, BTK and PLC-g2) as well as AKT1/2/
3 (panAKT) by flow cytometry and compared their baseline
(tonic) phosphorylation in CD19+ and CD19− BMPC with
CD27+CD38− BMBC as a control (Figure 1B). Cells were
gated according to the strategy showed in Figure S1.
Significant differences were detected for the expression of SYKFrontiers in Immunology | www.frontiersin.org 4and pSYK Y352 in contrast to the transcriptome data: CD19−
BMPC showed a significantly lower median fluorescence
intensities (MFI) of SYK and pSYK, which is downstream of
LYN as one of the proximal BCR kinases. For the PTKs BTK and
PLC-g2 further downstream of SYK in the BCR signaling
pathway and for the PSK AKT, which plays a role in survival
downstream of PI3K, we found a similar expression between the
two BMPC subsets. Likewise, there was no difference between the
two PC subsets for pBTK Y223, pPLC-g2 Y759, and pAKT S473.
Overall, CD27+CD38− BMBC displayed a lower expression of
PTKs except for SYK protein expression and pPLC-g2 Y759.
These findings emphasize that SYK and pSYKmay play a distinct
functional role in different BMPC subsets.
B Cell Receptor Stimulation Induces
Phosphorylation of B Cell Receptor-
Associated Kinases in Bone Marrow
Plasma Cell Subsets
IgA+ and IgM+ BMPC react to BCR stimulation (14) but whether
CD19 expression is related to differential responsivenessA B
FIGURE 1 | CD19+ and CD19− BMPC express BCR-associated kinases. (A) Gene expression profiling of CD19+ and CD19− BMPC. Expression of BCR
components and molecules involved in intracellular BCR signaling in CD19+ and CD19− BMPC. Dark blue indicates absent calls. Asterisks indicate significantly
different expression (Fold change CD19− vs CD19+ for CD19: −11, 87; CD45: −1, 67; CD32: −1, 46). (B) Median fluorescence intensities of the kinases SYK, BTK,
PLCg2 and AKT and their baseline phosphorylation among CD19+, CD19− BMPC and CD27+CD38− BMBC. Representative histogram of CD19+ (red lines) and
CD19− (blue lines) BMPC as well as CD27+CD38− BMBC staining (black lines) together with a FMO control (filled grey histogram). Bar represents mean, ****p <
0.0001, ***p < 0.001, **p < 0.01, *p < 0.05 by Friedman-Test with Dunn’s correction for multiple comparisons. SYK/pSYK (Y352): n = 28; PLC-g2: n = 29, pPLC-g2
(Y759): n = 8, BTK/pBTK (Y223): n = 28, AKT: n = 9, pAKT (S473): n = 33.February 2021 | Volume 11 | Article 628923
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PLC-g2 and AKT is induced after BCR stimulation (Figure 2A).
For CD19+ and CD19− PC, phosphorylation reached its
maximum after 2 min (pBTK Y223, pPLC-g2 Y759) or 5 min
(pSYK Y352, pAKT S473) (Figure 2A). Significant differences
between CD19+ and CD19− BMPC during BCR stimulation
kinetics were found for all time points after stimulation when
looking at SYK phosphorylation with consistently higher values
for CD19+ BMPC and pAKT at early time points (2 and 8 min).
The BCR response of CD27+CD38− BMBC (16, 22) served as
positive and T cells as negative control (Figure S2).
We wondered if BCR stimulation might lead to a loss of
CD19 expression possibly related to a differentiation of CD19+
BMPC into CD19− PC. During the short-term stimulation of
30 min, no change of the frequency of CD19− BMPC could be
detected (Figure 2B). More importantly, we observed no
changes in the frequency of CD19− BMPC during a four-day
culture upon anti-BCR stimulation (Figure 2C). Absolute
numbers of CD19+ and CD19− BMPC decreased during the
first day of culture but remained stable afterwards (Figure 2C)
indicating that the relative proportion and the expression of
CD19 did not change.Frontiers in Immunology | www.frontiersin.org 5IgA+ but Not IgG+ Bone Marrow Plasma
Cells Respond to B Cell Receptor
Stimulation
Since surface BCR expression on total BMPC has been described
before (7, 14, 15), we addressed how the differences between
CD19+ and CD19− BMPC and their distinct BCR reactivity
might be related to their isotype expression.
First, we compared surface and intracellular expression of IgA,
IgM and IgG on CD19+ and CD19− PC (Figure 3A). IgA+ PC were
found more frequently among CD19+ BMPC whereas more than
half of CD19− BMPC expressed IgG. We could also detect
comparable frequencies of IgA+ cells with surface membrane and
intracellular staining methods (surface: CD19+ 40.1%, CD19− 23.9%,
intracellular: CD19+ 43.1%, CD19− 31.4%), whereas for IgG, no
surface expression could be detected. Intracellular staining of IgG
revealed that 58.8% of CD19+ PC expressed IgG and 67.8% of CD19−
PC. As control, IgG surface expression was readily detectable on
CD27+ BMBC in the same staining (Figure 3B). IgM was only
detectable at very low frequencies on human BMPC subsets (~2% of
CD19+/CD19− PC). Thus, BCR surface expression was largely
limited to IgA+ PC and a substantially lower IgM+ fraction.A B
C
FIGURE 2 | CD19+ and CD19− BMPC respond to BCR stimulation. (A) MNCs isolated from the BM were stimulated with 30 µg/ml anti-BCR F(ab)2 IgM/IgG/IgA
(aBCR) for the indicated times and stained intracellularly for the respective phosphosites of different PTKs or PSK. A representative histogram is shown for each
pPTK/pPSK (5′ RPMI/5′ aBCR). For pSYK and pAKT, the median fluorescence intensity of total CD19+ or CD19− BMPCs is displayed. High expressors were gated
for pBTK and pPLC-g2 and the MFI is shown for this population. **p < 0.01, *p < 0.05 by Wilcoxon signed rank test. ns, not significant. pSYK: n = 10 (t = 15 min,
n = 9); pBTK: n = 10; pPLC-g2: n = 4; pAKT: n = 10. Data are presented as mean ± SD. (B) Frequency of CD19− PC among total BMPC during short-term BCR
kinetics. (C) BM MNCs were cultured for up to four days in the presence of 1 µg/ml anti-BCR F(ab)2 IgM/IgG/IgA (aBCR) or medium (control). Frequency of CD19
−
BMPC among total PC (n = 6–16) and absolute counts of CD19+ and CD19− BMPC (n = 5–12) during the culture with anti-BCR.February 2021 | Volume 11 | Article 628923





FIGURE 3 | IgA+ BMPC are responsible for enhanced phosphorylation of PTKs after BCR stimulation. (A) Surface and intracellular staining of IgA, IgM and IgG in
BMPC. Representative histograms of one out of three experiments (left), bar indicates gate for Ig+ cells. Filled grey histograms indicate the PC FMO control, the solid
line indicates staining of Ig. Numbers indicate mean of the frequency of Ig+ among each subset (n = 3). Frequencies for surface and intracellular Ig expression from
three experiments (right), bar indicates mean. (B) IgA and IgG surface staining of CD27+CD38− memory BMBC. (C) mRNA expression for BCR associated genes in
CD19+IgA+, CD19+IgA−, CD19−IgA+ and CD19−IgA− BMPC shown by log2(CPM+1) values. n = 2. (D, E) BM MNCs were either stimulated with 10 µg/ml anti-IgA F
(ab)2 (aIgA), 10 µg/ml anti-IgG F(ab)2 (aIgG) or 30 µg/ml anti-BCR F(ab)2 IgM/IgG/IgA (aIgM/IgG/IgA) for 5 min and stained for pSYK (Y
352) (D, n = 5–6) or pBTK
(Y223) (E, n = 7). A representative histogram is shown for each subset (solid lines: 5′anti-BCR; filled grey histogram: 5′RPMI). Significance was tested with Friedman-
Test with Dunn’s correction for multiple comparisons.Frontiers in Immunology | www.frontiersin.org February 2021 | Volume 11 | Article 6289236
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expression display a unique expression of BCR related
molecules. To do so, we sorted CD19+IgA+, CD19+IgA−,
CD19−IgA+ and CD19−IgA− and analyzed their transcriptomes
using RNA Seq. Purity of the sorted populations was checked
after the sort by flow cytometry (Figure S3A) as well as by CD19
and Ig isotype expression in the sorted samples (Figure S3B)
validating the sorting parameters. PC identity could be
confirmed by expression of e.g. CD138, BLIMP1, and IRF-4
(Figure 3C) and the J-chain was expressed in all four subsets. We
analyzed BCR associated molecules in the four subsets after
mRNA sequencing (Figure 3C) and found that all four subsets
defined by IgA and CD19 express BCR associated molecules on
the transcriptional level.
To address if BCR reactivity was linked to isotype expression
in CD19+ and CD19− BMPC, we stained pSYK Y352 or pBTK
Y233 together with IgA after BCR stimulation. Of interest, these
experiments revealed that IgA+ PC are responsible for increased
phosphorylation in both CD19+ and CD19− PC (Figures 3D, E).
After stimulation with anti-IgM/IgG/IgA, the MFIs of pSYK and
pBTK increased in CD19+IgA+ and CD19−IgA+ PC, whereas
CD19+IgA− and CD19−IgA− PC did not show increased MFIs of
pPTKs. This result was confirmed by stimulation with anti-IgG
or anti-IgA alone. Stimulation with anti-IgA led to similar MFIs
of pSYK Y352 and pBTK Y223 in both CD19+IgA+ and
CD19−IgA+ PC compared to stimulation with anti-IgM/IgG/
IgA, whereas for stimulation with anti-IgG alone, no increase of
pPTK MFI was detected. When comparing the response of
CD19+IgA+ and CD19−IgA+ PC, no significant difference
was observed.
Pre-incubation with SYK and BTK inhibitors and subsequent
anti-IgA stimulation resulted in reduced phosphorylation of
pSYK and pBTK in both CD19+IgA+ and CD19−IgA+ PC
compared to control. The SYK inhibitor entospletinib led to a
significant reduction of 68% (CD19+IgA+) and 62%
(CD19−IgA+) (Figure S3C, left), respectively. The BTK
inhibitor acalabrutinib resulted into a significant reduction of
35% (CD19+IgA+) and 40% (CD19−IgA+) (Figure S3C, right),
respectively suggesting a prominent role for SYK in BMPC
BCR signaling.
We further compared the stimulation response of the IgA1-
and IgA2-expressing subpopulations. No difference between
IgA1 and IgA2-expressing cells inside each CD19 subset was
found in terms of pSYK Y352 and pBTK Y223 phosphorylation,
respectively or for IgA1- or IgA2-expressing cells between
CD19+ and CD19− PC (Figure S3D, E). Of note, the majority
of IgA-expressing cells among BMPC were of the IgA1 isotype
(CD19+ 46 ± 10%, CD19− 30 ± 11% of total PC) and as little as
4% of total PC expressed IgA2 in each subset (Figure S3F).
Inhibitory Molecules Are Expressed by
Bone Marrow Plasma Cell Subsets
Activation of B cells via the BCR leads to upregulation of
activating as well as inhibitory markers to counterbalance
immune activation, like e.g. checkpoint molecules (23). We
asked if these molecules are functionally related to BCRFrontiers in Immunology | www.frontiersin.org 7stimulation in BMPC as B cells in the periphery upregulate
PD-1 upon in vitro stimulation (24). First, we assessed
expression of PD-1, PD-1 ligand (PD-L1), B and T
lymphocyte attenuator (BTLA), T cell immunoglobulin and
mucin-domain containing-3 (TIM-3) and Lymphocyte-
activation gene 3 (LAG-3) as well as CD28 at baseline
(Figure 4). We observed higher expression of PD-1 on
CD19− BMPC compared to CD19+ BMPC independently of
their isotype (Figure 4A). PD-L1, a ligand of PD-1, was also
found to be somewhat higher expressed on CD19− compared to
CD19+ PC. PC without Ig surface expression expressed lower
levels than PC subsets with Ig surface expression (Figure 4B).
Moreover, BMPC subsets expressing IgA or IgM on their
surface showed significantly higher BTLA expression
compared to BMPC lacking Ig surface expression at baseline
independently of their CD19 expression (Figure 4C). We did
not detect any TIM-3 or LAG-3 expression in human BMPC
(data not shown). The co-stimulatory molecule CD28 was
found to be higher expressed in CD19− BMPC of all isotypes
(Figure 4D). The distinct baseline expression of PD-1, PD-L1,
BTLA, and CD28 indicate that certain BMPC subsets follow
different functional directions.
IgA+ Bone Marrow Plasma Cells Uniquely
Upregulate Programmed Cell Death
Protein-1 Following B Cell Receptor
Stimulation
To address the functional outcome of BCR stimulation of
BMPCs, we cultured BM MNCs for up to four days with
anti-BCR or CD40L as control (Figure 5, Figure S4). Here,
PD-1 was upregulated by 28.3 ± 7.4% (CD19+) and 28.2 ± 9.6%
(CD19−) of IgA-expressing BMPC following BCR stimulation
compared to medium control (Figure 5A, left) without signs of
proliferation (data not shown). This upregulation was maximal
on day 1, declined towards day 2 and remained stable until the
end of the study (day 4), but was still higher than in the medium
control. BMPC lacking IgA on the surface did only show
upregulation of PD-1 by less than 10% (Figure 5A, right).
Assessment of the absolute number of PD-1+ cells after BCR
stimulation revealed a similar pattern as seen for the frequency:
IgA-expressing cells showed enhanced numbers of PD-1–
expressing cells, whereas in IgA− BMPC, only a minor
increase was detected (Figure 5B). Of note, the few IgM+
BMPC analyzed also upregulated PD-1 due to BCR
stimulation (Figure 5C). After incubation with CD40L alone
as a control, PC did not upregulate PD-1 (<5%) (Figure S4A)
suggesting that this upregulation is restricted to BCR
stimulation. Combined stimulation of the BCR and CD40 did
not lead to increased PD-1 frequencies compared to stimulation
of the BCR alone (data not shown). Staining for the checkpoint
molecules BTLA and PD-L1 after BCR stimulation showed no
upregulation of the respective molecules on BMPC but BTLA
expression decreased independently of the culture condition
(Figure 5D, S4B). CD28 expression, which was found to be
enhanced on CD19− BMPC at baseline, did not change upon
BCR stimulation (Figure S4C). When seeding BMPC enrichedFebruary 2021 | Volume 11 | Article 628923
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incubation conditions, we observed upregulation of PD-1 upon
BCR stimulation on IgA+ cells in both CD19+ and CD19− PC
(Figure S4D). In this experiment, 74.5% of the cell suspension
represented PC, whereas prior to enrichment, the percentage
was as low as 1.34% (Figure S4D). Taken together, IgA-
expressing BMPC are not only capable of signaling via BCR-
associated kinases, but also able to upregulate the co-inhibitory
molecule PD-1, a characteristic function in response to
BCR stimulation.
Inhibition of Spleen Tyrosine Kinase
Abrogates Programmed Cell Death
Protein-1 Upregulation in Human Bone
Marrow Plasma Cell
SYK and pSYK were significantly higher expressed in CD19+
compared to CD19− BMPC, and the SYK inhibitor entospletinib
could substantially diminish phosphorylation of SYK due to BCR
stimulation. Since we observed upregulation of PD-1 on IgA-
expressing PC after one day of BCR stimulation in human BMPC
cultures, we wondered if SYK might interfere with this effect. For
this purpose, we incubated BMMNCs with entospletinib prior to
BCR stimulation. Indeed, we could detect a major reduction of
PD-1+ cells among IgA+ and IgM+ BMPC due to the SYK
inhibitor which was comparable to the frequencies in the
medium control (Figure 5E). This is reflected in 96.75%
(CD19+IgA+), 86.5% (CD19−IgA+), 92.4% (CD19+IgM+) and
99.13% (CD19−IgM+) of inhibition. For IgA−IgM− BMPC,
comparable values were found for the different incubation
conditions. Thus, SYK still plays a major role in BCR signal
transduction in human BMPC.Frontiers in Immunology | www.frontiersin.org 8DISCUSSION
The function of BMPC in addition to antibody production is not
yet fully understood. It is commonly believed that the BCR is not
expressed on BMPC and that no remaining function is associated
with its expression.
Here we analyzed the downstream BCR signaling in human
BMPC together with CD19 expression. We found that BCR
responsiveness of BMPC did not uniquely depend on CD19
expression as a major costimulatory molecule of BCR signaling
(25) as BCR-associated molecules were found on the mRNA level
for both CD19− and CD19+ subsets (Figures 1 and 3). Notably,
CD19 expression was not influenced by BCR stimulation and
remained stable in vitro (Figure 2C). This result suggests that
BCR engagement does not impact on CD19 expression on BMPC.
Until now, to our knowledge, no mechanism that leads to a distinct
expression of CD19 on BMPC has been proposed, which allows the
hypothesis that both subsets are generated simultaneously.
SYK and pSYK Y352 were higher expressed in CD19+ BMPC at
baseline and after stimulation. During BCR stimulation, SYK has
been reported to play a key role in transmission of the activation
signal into the cell (26, 27). This indicates that SYK in contrast to
BTK appears to be also crucial for transmitting signals in PCs.
When taking Ig isotype expression into account, IgA+ BMPC in
both CD19+ and CD19− BMPC showed enhanced protein kinase
phosphorylation after BCR activation which confirms prior findings
that IgA-(and IgM)-expressing BMPC are able to react to BCR
stimulation (14). Since CD19+ BMPC contain more IgA-expressing
cells than their CD19− counterparts, it provides the explanation of
higher phosphorylation in response to BCR stimulation when only
CD19 expression during stimulation kinetics has been considered.A B
C D
FIGURE 4 | CD19− BMPC express higher levels of PD-1 than CD19+. Baseline expression of PD-1 (A, MFI), PD-L1 (B, MFI), BTLA (C, MFI) and CD28 (D,
frequency) was assessed in IgA+, IgM+ and IgA−IgM− BMPC. A representative histogram with the respective isotype control staining (filled grey histogram: isotype
control, solid lines: staining of CD19+/− BMPC) and cumulative data is shown (n = 8–33) for IgA+, IgM+ and IgA−IgM− BMPC. Bars indicate mean. ****p < 0.0001,
***p < 0.001, **p < 0.01, *p < 0.05 by Friedman-Test with Dunn’s correction for multiple comparisons.February 2021 | Volume 11 | Article 628923
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responsiveness in PC, similar phosphorylation of PTKs by IgA+
BMPC was detected independently of CD19 expression (Figures
3D, E). Similarly, in mice, the presence or absence of CD19 did not
have an impact on the calcium response induced by IgM-
crosslinking (25). In another study, two functionally distinct
populations of murine BMPC defined by the Ig isotype (IgM and
IgG) were described: IgM+ BMPC displayed a modified gene
expression profile and enhanced production of CCL5 and IL-10
after antigenic boost, whereas IgG+ BMPC did not express a
functional BCR (15). However, these results might not be directly
translatable to human BM since only around 2% to 5% of human
BMPC express IgM. In human BMPC, BCR crosslinking led toFrontiers in Immunology | www.frontiersin.org 9increased phosphorylation of SYK and ERK in IgA+ and IgM+
BMPC as well as to enhanced calcium influx and survival in vitro
(14). When we included Ig isotypes in our analysis of BCR
responsiveness, we saw that IgA+ (and the few IgM+) BMPC
responded to BCR stimulation independently of the presence of
absence of CD19.
IgA-expressing cells comprise 30% to 65% in the CD19+ and
around 15% to 56% in the CD19− BMPC subset in our cohort. It
was described that rotavirus-specific IgA+ BMPC were present
decades after exposure of individuals to the virus and thus can
most likely also be considered as long-lived (7). In humans, both
CD19+ and CD19− PC are found in the gut and the majority of




FIGURE 5 | PD-1 is upregulated on IgA-expressing BMPC following BCR stimulation. BM MNCs were cultured for up to four days in the presence of 1 µg/ml anti-
BCR F(ab)2 IgM/IgG/IgA (aBCR) or medium (control). (A) A representative histogram of PD-1 is shown (filled grey: staining d1 medium control; solid lines: staining d1
aBCR). PD-1 expression on IgA+ (left) and IgA− (right) BMPC was analyzed among the subsets defined by CD19. Mean ± SD; n = 6–16 for each timepoint, Kruskal-
Wallis-Test with Dunn’s correction for multiple comparisons. *p < 0.001, **p < 0.0001. (B) Absolute cell counts of PD-1+ cells during the culture with anti-BCR
among IgA+ (left) and IgA− (right) BMPC of CD19+ and CD19− BMPC. Mean ± SD; n = 5–12 for each timepoint, Kruskal-Wallis-Test with Dunn’s correction for
multiple comparisons. *p < 0.001. (C) PD-1 expression on IgM+ BMPC was analyzed among the subsets defined by CD19. Mean ± SD; n = 4–9 for each timepoint,
Kruskal-Wallis-Test with Dunn’s correction for multiple comparisons. (D) Representative histogram (d1 medium control and aBCR) of BTLA (MFI) and cumulative data
of IgA+ and IgA− CD19+/− BMPC after BCR stimulation. n = 2–16 for each timepoint. (E) BM MNCs were incubated with SYK inhibitor entospletinib or DMSO as a
control 30 min prior to stimulation with anti-BCR for 1 day and stained for PD-1 together with CD19, IgA and IgM. Frequency of PD-1+ cells from stimulated samples
minus unstimulated controls (D%) for the BMPC subsets defined by CD19, IgA and IgM, bar indicates mean, n = 3.February 2021 | Volume 11 | Article 628923
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whereas polymeric IgA is induced in the gastro-intestinal tract.
In the transcriptomes of the BMPC analyzed, we found the J-
chain to be expressed, which thus would favor induction in the
gut. A less stringent compartmentalization between systemic and
mucosal immunity has been suggested after discovering that
murine IgA+ PC generated by oral immunization in the gut can
be found for up to three months in the BM (29). In mice, certain
commensal bacteria are able to induce enhanced levels of serum
IgA as well as the presence of IgA-expressing PC in the BM (30).
However, current evidence does not exclude that IgA versus IgG
BMPC are generated during the same immune activation but
taking different routes of B cell activation using possibly distinct
checkpoint molecule and cytokine activation patterns.
Remarkably, we observed a unique upregulation of PD-1 in
about one third of IgA+ (and the few IgM+) BMPC in response to
BCR stimulation, which is characteristic for peripheral B cells
after stimulation to counterregulate immune activation (Figure
5A) (24), whereas IgA− BMPC showed no substantial increase of
PD-1 expression. The upregulation of PD-1 could lead to a
regulatory effect on other cells of the immune system as IgA-
expressing PC in the murine gut were able to induce regulatory T
cells (Treg) in the presence of TGF-b, which suggests that IgA+
PC might play an immune regulatory role (31). In the BM of
mice, contact of BMPC and Tregs by CD28 and CTLA4 was
detected by intravital imaging (32) and signaling via the PD-L1/
PD-1 axis in Tregs is thought to play a key role in the
maintenance and function of the negative regulation of
immune responses (33, 34). Our results raise the question if
IgA+ BMPC are involved in this counterregulation mediated by
Tregs. Recently, two different mouse studies described regulatory
functions for PC: recirculating IL-10–producing IgA+ PC
induced in the gut suppress neuroinflammation in a mouse
model of autoimmune encephalomyelitis (EAE) (35) and IL-
10–producing IgM+ PC are natural regulatory PC that can be
identified by their LAG-3 expression (36).
Of note, upregulation of PD-1 could be almost completely
inhibited by SYK inhibitor entospletinib in BMPC subsets with
Ig surface expression (Figure 5E). SYK is a prominent kinase
expressed in B cells that couples BCR activation to all relevant
downstream pathways (37), but also plays a role in CpG-induced
activation (38). This finding emphasizes the role of SYK in signal
transduction for at least a subset of BMPC and may open
innovative possibilities to target these specific cells.
We here identify that IgA-expressing human BMPC are able
to respond to antigen encounter with a BCR response translating
intracellular signaling and a characteristic PD-1 upregulation
independent of CD19 expression. In addition to the emerging
phenotypic heterogeneity, the data indicate a functional
heterogeneity of mature PC beyond antibody production.DATA AVAILABILITY STATEMENT
All data relevant is contained within the article. The sequence
data presented in the study has been deposited at the EuropeanFrontiers in Immunology | www.frontiersin.org 10Genome-phenome Archive (EGA), which is hosted by the EBI
and the CRG, under accession number EGAS00001004948.ETHICS STATEMENT
The studies involving human participants were reviewed and
approved by the local ethics committee of Charité
Universitätsmedizin Berlin. The patients/participants provided
their written informed consent to participate in this study.AUTHOR CONTRIBUTIONS
The concept of the study was planned by AW, AL, and TD.
Experiments were conducted, analyzed, and interpreted by AW,
ML, IW, and AL. Sample preparation for mRNA Seq,
sequencing, and subsequent analysis were done by AJ, AS, GG,
and JW. Samples were provided by the Department of CP. AW
drafted the manuscript. AL, HEM, AR, and TD edited the
manuscript and provided advice. All authors contributed to the
article and approved the submitted version.FUNDING
This work was supported by grants from the German Research
Foundation Do 491/8-1/2 (SPP Immunobone), TRR130/TP24,
Do491/10-1, 11-1 and LI3540/1-1. AS was supported by the
German Federal Ministry of Research and Education grant for
de.NBI (031L0101D).ACKNOWLEDGMENTS
We would like to thank all BM donors as well as Simon Reinke
and Antje Blankenstein from the BCRT Cell Harvesting
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